Welcome to our dedicated page for Cytokinetics SEC filings (Ticker: CYTK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Cytokinetics, Incorporated (CYTK) SEC filings page on Stock Titan brings together the company’s public reports filed with the U.S. Securities and Exchange Commission. Cytokinetics is a Nasdaq-listed specialty cardiovascular biopharmaceutical company focused on muscle biology and diseases of cardiac muscle dysfunction, and its filings provide detailed information about its operations, capital structure and regulatory progress.
Recent Form 8-K current reports from Cytokinetics include disclosures about regulatory milestones for MYQORZO (aficamten), such as a positive opinion from the Committee for Medicinal Products for Human Use of the European Medicines Agency for symptomatic obstructive hypertrophic cardiomyopathy. Other 8-K filings describe financial results, the issuance of convertible senior notes due 2031, planned draws under a development funding loan agreement and executive appointments and compensation arrangements.
Investors reviewing CYTK filings can also track information about the company’s listing on The Nasdaq Global Select Market, its equity incentive plans, inducement grants under Nasdaq Listing Rule 5635(c)(4) and its use of proceeds from capital raises to support the potential commercial launch of aficamten and the advancement of its development pipeline. Additional SEC documents, such as annual and quarterly reports when available, typically include discussions of clinical programs in hypertrophic cardiomyopathy and heart failure, risk factors and financial statements.
On Stock Titan, these SEC filings are updated as new documents are released on EDGAR, and AI-powered tools can help summarize key points from lengthy reports so readers can more quickly understand the context and implications of Cytokinetics’ regulatory and financial disclosures.
Cytokinetics EVP of Research & Development Fady Ibraham Malik exercised options and sold shares of company stock. He exercised non-qualified stock options for 3,500 shares of Common Stock at $7.80 per share, then completed an open-market sale of 3,500 Common Stock shares at $65.69 per share on the same date. Following these transactions, he directly holds 153,902 shares of Common Stock.
Cytokinetics, Incorporated is asking stockholders to vote at its May 27, 2026 annual meeting on board elections, equity incentives, auditor ratification and executive pay. Three Class I directors are up for re-election to serve until the 2029 annual meeting.
Stockholders are asked to approve an amendment to the 2015 Employee Stock Purchase Plan adding 1,000,000 shares, raising the total reserve to 2,459,879 shares, which the company estimates would increase ESPP-related dilution from about 1.2% to about 2.0%. The agenda also includes ratifying Ernst & Young as independent auditor for 2026 and an advisory “say-on-pay” vote on 2025 compensation for named executive officers.
CYTOKINETICS INC director Nancy Wysenski received a grant of 95 shares of Common Stock valued at $65.37 per share. The award was made as part of the Director Equity in Lieu of Cash Retainer Program and is fully vested. Following this compensation-related acquisition, she directly owns 31,066 shares of Common Stock.
Cytokinetics director Wendell Wierenga received a stock grant of 95 shares of Common Stock as part of the company’s Director Equity in Lieu of Cash Retainer Program. The shares are fully vested, meaning they are not subject to additional service conditions.
Following this equity award, Wierenga directly holds a total of 32,637 shares of Cytokinetics Common Stock. This Form 4 reflects a routine compensation-related acquisition rather than an open-market purchase or sale.
Kaye Edward M. MD reported acquisition or exercise transactions in this Form 4 filing.
Cytokinetics Inc director Edward M. Kaye, MD received 191 shares of Common Stock as an equity grant. The shares were granted under the Director Equity in Lieu of Cash Retainer Program at a reference price of $65.37 per share and are fully vested. Following this compensation-related award, he directly holds 10,365 shares of Cytokinetics common stock.
HENDERSON JOHN T reported acquisition or exercise transactions in this Form 4 filing.
Cytokinetics director John T. Henderson received 325 shares of Common Stock as equity compensation instead of a cash retainer. The award was granted under the Director Equity in Lieu of Cash Retainer Program and is fully vested. Following this grant, he directly holds 75,237 shares, with an additional 83 shares held indirectly through his spouse.
Harrington Robert Arthur reported acquisition or exercise transactions in this Form 4 filing.
CYTOKINETICS INC director Robert Arthur Harrington received a grant of 191 shares of Common Stock as equity compensation. The shares were granted under a Director Equity in Lieu of Cash Retainer Program and are fully vested, meaning he owns them outright. Following this award, he directly holds 18,930 shares of CYTOKINETICS INC common stock.
Daly James M reported acquisition or exercise transactions in this Form 4 filing.
CYTOKINETICS INC director James M. Daly received 191 shares of common stock as a fully vested equity award under the Director Equity in Lieu of Cash Retainer Program. The shares were valued at $65.37 each on the grant date. After this award, Daly directly holds 388 CYTK common shares.
CYTOKINETICS INC executive Andrew Callos reported an open-market sale of company stock. As EVP and Chief Commercial Officer, he sold 7,449 shares of Common Stock at a price of $66.02 per share. Following this transaction, he directly holds 58,555 shares of CYTOKINETICS INC Common Stock.